<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2182-5173</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Medicina Geral e Familiar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Med Geral Fam]]></abbrev-journal-title>
<issn>2182-5173</issn>
<publisher>
<publisher-name><![CDATA[Associação Portuguesa de Medicina Geral e Familiar]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2182-51732024000200148</article-id>
<article-id pub-id-type="doi">10.32385/rpmgf.v40i2.13647</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[SGLT2i pharmacological treatment in type 2 diabetes mellitus control and its underlying obesity]]></article-title>
<article-title xml:lang="pt"><![CDATA[Terapêutica farmacológica com SGLT2i no controlo da diabetes mellitus tipo 2 e na obesidade associada]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Santiago]]></surname>
<given-names><![CDATA[Luiz Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[Mariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Oliveiros]]></surname>
<given-names><![CDATA[Barbara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade de Coimbra Faculdade de Medicina Clínica Universitária de Medicina Geral e Familiar]]></institution>
<addr-line><![CDATA[Coimbra ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade de Coimbra Centro de Estudos e Investigação em Saúde ]]></institution>
<addr-line><![CDATA[Coimbra ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidade de Coimbra Faculdade de Medicina ]]></institution>
<addr-line><![CDATA[Coimbra ]]></addr-line>
<country>Portugal</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidade de Coimbra Faculdade de Medicina ]]></institution>
<addr-line><![CDATA[Coimbra ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>04</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>04</month>
<year>2024</year>
</pub-date>
<volume>40</volume>
<numero>2</numero>
<fpage>148</fpage>
<lpage>156</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2182-51732024000200148&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2182-51732024000200148&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2182-51732024000200148&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Aim:  To compare obesity progression and the type2 diabetes mellitus (T2DM) metabolic control between 2017 and 2019, according to sodium-glucose cotransporter type 2 inhibitors (SGLT2i) or not therapy, in the T2D population of the Central Administrative Portuguese National Health Service Authority, the ARS do Centro.  Methods:  Observational retrospective cohort study in 2021 of data by the informatic services of ARS do Centro, after ethics consent: gender, age, year of ICPC2 T90 classification, abdominal perimeter (AP), body mass index (BMI), last glycated haemoglobin (HbA1c) in 2017 and 2019 and drugs registered in the e.registration official program, the S-Clínico Diabetes.  Results:  Out of the 127,062 T2DM patients of the ARS do Centro n=16.012 (12.6%) were on SGLT2i in 2017. The mean age was 73.5±10.1 years, the time since ICPC classification was 8.7±4.2 years and 48.8% were males. HbA1C, BMI and AP values between 2017 and 2019 were independent for age and time since diagnosis, |rS| &lt;0.400. Median HbA1c values between the two moments, in the total sample and the subgroups medicated with SGLT2i and per gender were significantly different (p&lt;0.001) values increasing. No difference was observed in the subgroups not SGLT2i treated, either globally (p=0.983) or per gender (M: p=0.932; F: p=0.932). BMI in SGLT2i treated T2DM showed significant negative variation (p&lt;0.001) also observed in nonSGLT2i treated ones (p=0.004). AP values significantly increased in nonSGLT2i T2DM patients (p=0.001) and significantly decreased in the SGLT2i treated ones (p&lt;0.001).  Discussion:  The efficacy of SGLT2i in clinical assays and its effectiveness in real-world patients must be ascertained. Obesity decrease in BMI or AP can contribute to future T2DM analytics control.  Conclusion:  SGLT2i significantly decreased BMI and prevented AP increase, compared to non-SGLT2 T2DM patients. HbA1c control, in a 2-year gap, showed no decrease in growth.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Objetivo:  Comparar a progressão da obesidade e do controlo metabólico entre 2017 e 2019, pela terapêutica farmacológica com inibidores da SGLT2 (iSGLT2) em doentes com diabetes mellitus tipo 2 (DM2) na área da Administração Regional de Saúde do Centro (ARS Centro).  Métodos:  Estudo observacional de coorte retrospetiva em 2021, segundo dados fornecidos pelos serviços informáticos da ARS Centro, após consentimento ético institucional quanto a sexo, idade, ano de classificação DM2, perímetro abdominal (PA), índice de massa corporal (IMC), última avaliação de HbA1c em 2017 e em 2019 e medicamentos assinalados no programa S-Clínico de diabetes.  Resultados:  De 127.062 doentes com DM2, 16.012 (12,6%) estavam medicados com iSGLT2, 48,8% do sexo masculino, a idade média de 73,5±10,1 anos e o tempo desde classificação DM2 de 8,7±4,2 anos. Para HbA1C, IMC e PA entre ambos os pontos de análise mostraram-se independentes da idade e do tempo desde o diagnóstico: |rS|&lt;0,400. Verificou-se diferença significativa entre os valores medianos de HbA1c em 2017 e 2019 no total e nos subgrupos medicados com SGLT2i, globalmente e por sexo (p&lt;0,001). Nos não medicados com iSGLT2 não foi observada diferença significativa globalmente (p=0,983) e por sexo (M: p=0,932; F: p=0,932). O IMC em sujeitos sob iSGLT2 reduziu significativamente (p&lt;0,001) como no grupo medicado com outros fármacos (p=0,004). O PA aumentou significativamente no grupo não iSGLT2 (p=0,001) e teve redução significativa no grupo sob SGLT2i (&lt;0,001).  Discussão:  A eficácia dos iSGLT2 observada em ensaios clínicos deve ser verificada em doentes do mundo real, a efetividade. A redução da obesidade por IMC e por PA pode ser fator de futuro controlo de DM2.  Conclusão:  A terapêutica com iSGLT2 reduziu significativamente o IMC e o PA em comparação com o grupo controlo. O controlo da DM2 pela HbA1c neste espaço de dois anos não revelou crescimento.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Type 2 diabetes mellitus]]></kwd>
<kwd lng="en"><![CDATA[SGLT2i]]></kwd>
<kwd lng="en"><![CDATA[Medicines treatment]]></kwd>
<kwd lng="en"><![CDATA[Obesity]]></kwd>
<kwd lng="en"><![CDATA[Control]]></kwd>
<kwd lng="pt"><![CDATA[Diabetes mellitus tipo 2]]></kwd>
<kwd lng="pt"><![CDATA[Inibidores da SGLT2]]></kwd>
<kwd lng="pt"><![CDATA[Tratamento farmacológico]]></kwd>
<kwd lng="pt"><![CDATA[Obesidade]]></kwd>
<kwd lng="pt"><![CDATA[Controlo]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Highlighting diabetes mellitus the epidemic continues]]></article-title>
<source><![CDATA[Arterioscler Thromb Vasc Biol]]></source>
<year>2018</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e1-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>International Diabetes Federation</collab>
<source><![CDATA[IDF clinical practice recommendations for managing type 2 diabetes in primary care]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Brussels ]]></publisher-loc>
<publisher-name><![CDATA[IDF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and diabetes an update]]></article-title>
<source><![CDATA[Diabetes Metab Syndr]]></source>
<year>2017</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>73-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[2 Classification and diagnosis of diabetes: standards of medical care in diabetes-2019]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2019</year>
<volume>42</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S13-28</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Diagnosis and classification of diabetes mellitus]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2012</year>
<volume>35</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S64-71</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yumuk]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Tsigos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fried]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schindler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Busetto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Micic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European guidelines for obesity management in adults]]></article-title>
<source><![CDATA[Obes Facts]]></source>
<year>2015</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>402-24</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Heisel]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Afshin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Dietz]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The science of obesity management an Endocrine Society Scientific statement]]></article-title>
<source><![CDATA[Endocr Rev]]></source>
<year>2018</year>
<volume>39</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>79-132</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Borlaug]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Bax]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabesity the combined burden of obesity and diabetes on heart disease and the role of imaging]]></article-title>
<source><![CDATA[Nat Rev Cardiol]]></source>
<year>2021</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>291-304</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piché]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Tchernof]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Després]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity phenotypes, diabetes, and cardiovascular diseases]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2020</year>
<volume>126</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1477-500</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chobot]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Górowska-Kowolik]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sokolowska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jarosz-Chobot]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and diabetes not only a simple link between two epidemics]]></article-title>
<source><![CDATA[Diabetes Metab Res Rev]]></source>
<year>2018</year>
<volume>34</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maggio]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Pi-Sunyer]]></surname>
<given-names><![CDATA[FX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and type 2 diabetes]]></article-title>
<source><![CDATA[Endocrinol Metab Clin North Am]]></source>
<year>2003</year>
<volume>32</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>805-22</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pulgaron]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Delamater]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesity and type 2 diabetes in children epidemiology and treatment]]></article-title>
<source><![CDATA[Curr Diab Rep]]></source>
<year>2014</year>
<volume>14</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>508</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>Administração Regional de Saúde do Centro</collab>
<source><![CDATA[Perfil regional de saúde (Região Centro)]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Coimbra ]]></publisher-loc>
<publisher-name><![CDATA[ARS Centro]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malone]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Does obesity cause type 2 diabetes mellitus (T2DM) Or is it the opposite?]]></article-title>
<source><![CDATA[Pediatr Diabetes]]></source>
<year>2019</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pothuraju]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Chagalamarri]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jangra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kavadi]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of Gymnema sylvestre in obesity and diabetes management]]></article-title>
<source><![CDATA[J Sci Food Agric]]></source>
<year>2014</year>
<volume>94</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>834-40</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Shui]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[BX]]></given-names>
</name>
<name>
<surname><![CDATA[Chin]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Yue]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The potential roles of artemisinin and its derivatives in the treatment of type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Front Pharmacol]]></source>
<year>2020</year>
<volume>11</volume>
<page-range>585487</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type 2 diabetes etiology and reversibility]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1047-55</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Melo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nunes]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Melo]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Raposo]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendações nacionais da SPD para o tratamento da hiperglicemia na diabetes tipo 2 atualização 2018/19 com base na posição conjunta ADA/EASD]]></article-title>
<source><![CDATA[Rev Port Diabetes]]></source>
<year>2018</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>154-80</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Häring]]></surname>
<given-names><![CDATA[HU]]></given-names>
</name>
<name>
<surname><![CDATA[Merker]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Seewaldt-Becker]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Weimer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meinicke]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Woerle]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes a 24-week, randomized, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2013</year>
<volume>36</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3396-404</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahiya]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kaur]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Palta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GLP-1 Receptor agonists in type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Curr Diabetes Rev]]></source>
<year>2020</year>
<volume>16</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>279-92</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cassis]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Locatelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cerullo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Corna]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Buelli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zanchi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy]]></article-title>
<source><![CDATA[JCI Insight]]></source>
<year>2018</year>
<volume>3</volume>
<numero>15</numero>
<issue>15</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2i beyond the glucose-lowering effect]]></article-title>
<source><![CDATA[Cardiovasc Diabetol]]></source>
<year>2020</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>98</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greco]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Giandalia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Viazzi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pontremoli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[De Cosmo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GLP-1 Receptor agonists and kidney protection]]></article-title>
<source><![CDATA[Medicina (Kaunas)]]></source>
<year>2019</year>
<volume>55</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>233</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meier]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Nat Rev Endocrinol]]></source>
<year>2012</year>
<volume>8</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>728-42</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vilsbøll]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Junker]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Knop]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
<name>
<surname><![CDATA[Gluud]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of glucagon-like peptide-1 receptor agonists on weight loss systematic review and meta-analyses of randomised controlled trials]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2012</year>
<volume>344</volume>
<page-range>d7771</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cuthbertson]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Newer GLP-1 receptor agonists and obesity-diabetes]]></article-title>
<source><![CDATA[Peptides]]></source>
<year>2018</year>
<volume>100</volume>
<page-range>61-7</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheen]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SGLT2 inhibitors as add-on therapy to metformin for people with type 2 diabetes a review of placebo-controlled trials in Asian versus non-Asian patients]]></article-title>
<source><![CDATA[Diabetes Metab Syndr Obes]]></source>
<year>2020</year>
<volume>13</volume>
<page-range>2765-79</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stefansson]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
<name>
<surname><![CDATA[Chertow]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Correa-Rotter]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2020</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>274-82</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hocher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury]]></article-title>
<source><![CDATA[Kidney Blood Press Res]]></source>
<year>2019</year>
<volume>44</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>149-57</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[6 Glycemic targets]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2017</year>
<volume>40</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>S48-56</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crowley]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Holleman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Klamerus]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Bosworth]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Edelman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Heisler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors associated with persistent poorly controlled diabetes mellitus clues to improving management in patients with resistant poor control]]></article-title>
<source><![CDATA[Chronic Illn]]></source>
<year>2014</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>291-302</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bijelic]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Balaban]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Milicevic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sipka]]></surname>
<given-names><![CDATA[SU]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association of obesity and microvascular complications with glycemic control in patients with type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Med Arch]]></source>
<year>2020</year>
<volume>74</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-8</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ang]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Age of onset of diabetes and all-cause mortality]]></article-title>
<source><![CDATA[World J Diabetes]]></source>
<year>2020</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>95-9</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azevedo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Santiago]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fiabilidade da Escala de Conhecimento da Diabetes em Portugal]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2016</year>
<volume>29</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>499-506</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aveiro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Santiago]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Simões]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudo de fiabilidade da Escala de Capacidade de Controlo da Diabetes versão breve]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2015</year>
<volume>28</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>177-81</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santiago]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Simões]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Vale]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Faria]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Rosendo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Auto perceção do desempenho da medicina centrada na pessoa em medicina geral e familiar criação de um instrumento de medição]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2020</year>
<volume>33</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>407-14</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
